COMMUNIQUÉS West-GlobeNewswire

Kainova Therapeutics Expands Phase I/II Trial of DT-7012, a Treg-depleting Anti-CCR8 Antibody, with First Patient Dosed in Europe
09/04/2026
First patient dosed in France, expanding the DOMISOL study beyond Australia DT ‑ 7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program MONTREAL and [...]
Ecuador Free of Rabies project accelerates progress toward eliminating dog-mediated rabies supported by Boehringer Ingelheim’s Stop Rabies program
09/04/2026
• Ecuador aims to become one of the first rabies free countries in Latin America. • Joint efforts with the Ministry of Public Health focus on vaccination, education and epidemiological surveillance. • Boehringer [...]
Losing Your Voice? Millions Experience Persistent Problems Each Year
09/04/2026
ASHA Shares Warning Signs of Voice Disorders and Tips To Protect Your Voice for World Voice Day Rockville, MD, April 09, 2026 (GLOBE NEWSWIRE) -- Most people will experience an occasional sore throat related to a cold [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Biliary Tract Cancer Following Positive Safety and Preliminary Efficacy Results
09/04/2026
NANJING, China, April 09, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) announced that its proprietary PD-L1/4-1BB bispecific antibody, Opamtistomig ( [...]
New Peer-Reviewed Publication Highlights Evidence of Mother-to-Child-Transmission of Lyme Disease Bacteria During Pregnancy and Calls for Urgent Research
09/04/2026
New paper in Frontiers in Medicine reports results of meeting of international researchers at the Banbury Center of Cold Spring Harbor Laboratory PORTOLA VALLEY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Bay Area Lyme [...]
Idorsia welcomes Amer Joseph as new Chief Medical Officer and Head of Global Clinical Development
09/04/2026
Idorsia thanks Alberto Gimona – most recently Head of Global Clinical Development and Medical Affairs – and wishes him all the best for a well-deserved retirement Amer Joseph joins Idorsia as EVP, Chief Medical Officer [...]
Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth
09/04/2026
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 9 April 2026 – 7:00 AM CET Fagron reports solid first-quarter revenue of €263 million, reflecting 10% topline growth Fagron, the leading global [...]
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference
09/04/2026
Vivoryon Therapeutics N.V. to Attend Upcoming Investor Conference Halle (Saale) / Munich, Germany, April 9 , 2026 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) ( Vivoryon ), a clinical stage [...]
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
09/04/2026
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical [...]
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026
Strengthens three community health models spanning community ‑ embedded care, earlier intervention and data ‑ driven population health Scales program footprint from 11 countries to more than 30 by 2030, including across [...]
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
09/04/2026
Strengthens three community health models spanning community‑embedded care, earlier intervention and data ‑ driven population health Scales program footprint from 11 countries to more than 30 by 2030, including across [...]
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
09/04/2026
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 09, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of [...]
Inventiva annonce le dépôt de son Document d’Enregistrement Universel 2025 et de son Rapport Annuel 2025 (« Form 20-F »)
08/04/2026
Daix (France), New York City (New York, Etats-Unis), le 8 avril 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’une [...]
Inventiva announces filing of its 2025 Universal Registration Document and 2025 Annual Report on Form 20-F
08/04/2026
Daix (France), New York City (New York, United States), April 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies [...]
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
08/04/2026
AX-0810 clinical target engagement data in healthy volunteers on track for this quarter; biliary atresia selected as initial Phase 2 indication Additional programs advancing toward the clinic, including AX-0811 and AX- [...]
Annexon to Present at the 25th Annual Needham Virtual Healthcare Conference
08/04/2026
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that [...]
Kyntra Bio to Present at the 25th Annual Needham Virtual Healthcare Conference
08/04/2026
SAN FRANCISCO, April 08, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the Company will present at the 25 th Annual Needham Virtual Healthcare Conference being held April 13-16, 2026. Thane [...]
NEXGEL Reschedules Shareholder Update Conference Call to April 15th at 4:30 P.M. ET to Provide Update on Celularity Transaction
08/04/2026
LANGHORNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high- [...]
RxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026
08/04/2026
WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ: RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light [...]

Pages